Patents Assigned to Xenon Pharmaceuticals
  • Substituted benzoxazoles and methods of use thereof
    Patent number: 9493429
    Abstract: The invention provides compounds having the general formula (I): and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 15, 2016
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Chien-An Chen, Sultan Chowdhury, Christoph Martin Dehnhardt, Shaoyi Sun
  • Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
    Patent number: 9487535
    Abstract: This invention is directed to asymmetric syntheses of certain spiro-oxindole derivatives, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: November 8, 2016
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Shaoyi Sun, Jianmin Fu, Sultan Chowdhury, Ivan William Hemeon, Michael Edward Grimwood, Tarek Suhayl Mansour
  • Biaryl ether sulfonamides and their use as therapeutic agents
    Patent number: 9481677
    Abstract: This invention is directed to biaryl ether sulfonamides, or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
    Type: Grant
    Filed: October 30, 2012
    Date of Patent: November 1, 2016
    Assignee: XENON PHARMACEUTICALS INC.
    Inventors: Shifeng Liu, Thilo Focken, Navjot Chahal, Zaihui Zhang, Renata Marcella Oballa, Julia Fonarev
  • Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
    Patent number: 9480677
    Abstract: This invention is directed to the (S)-enantiomer of the compound of formula (I): or a pharmaceutically acceptable solvate or prodrug thereof. This (S)-enantiomer is useful for the treatment of diseases or conditions, such as pain, which are ameliorated or alleviated by the modulation of voltage-gated sodium channels.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: November 1, 2016
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Mikhail Chafeev, Jianmin Fu, Jean-Jacques Alexandre Cadieux
  • N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF
    Publication number: 20160297754
    Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: April 19, 2016
    Publication date: October 13, 2016
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Sultan Chowdhury, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Daniel Ortwine, Brian Safina, Shaoyi Sun, Daniel P. Sutherlin, Alla Yurevna Zenova
  • ORGANIC COMPOUNDS
    Publication number: 20160289191
    Abstract: The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Application
    Filed: October 9, 2015
    Publication date: October 6, 2016
    Applicants: XENON PHARMACEUTICALS INC., NOVARTIS AG
    Inventors: Natalie Dales, Zaihui Zhang, Jianmin Fu, Duanjie Hou, Shaoyi Sun, Vishnumurthy Kodumuru, Natalia Pokrovskaia
  • Spiro-oxindole compounds and their use as therapeutic agents
    Patent number: 9458178
    Abstract: This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: October 4, 2016
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Mikhail Chafeev, Sultan Chowdhury, Lauren Fraser, Jianmin Fu, Jonathan Langille, Shifeng Liu, Jianyu Sun, Shaoyi Sun, Serguei Sviridov, Mark Wood, Alla Yurevna Zenova, Qi Jia, Jean-Jacques Alexandre Cadieux, Simon J. Gauthier, Amy Frances Douglas, Tom Hsieh, Nagasree Chakka, Zoran Cikojevic
  • Methods For Identifying Analgesic Agents
    Publication number: 20160166541
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of using compounds small organic compounds to treat pain as well as to predict the effect of analgesic agents in patients, such as those possessing gain of function mutations.
    Type: Application
    Filed: January 27, 2016
    Publication date: June 16, 2016
    Applicant: Xenon Pharmaceutical Inc.
    Inventors: Marcia MacDonald, Mark Samuels, Robin Sherrington, Yigal Paul Goldberg
  • Biaryl ether sulfonamides and their use as therapeutic agents
    Patent number: 9365578
    Abstract: This invention is directed to biaryl ether sulfonamides, or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
    Type: Grant
    Filed: October 30, 2012
    Date of Patent: June 14, 2016
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Shifeng Liu, Thilo Focken, Navjot Chahal, Zaihui Zhang, Renata Marcella Oballa, Julia Fonarev
  • Methods for identifying analgesic agents
    Patent number: 9278088
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of using compounds small organic compounds to treat pain as well as to predict the effect of analgesic agents in patients, such as those possessing gain of function mutations.
    Type: Grant
    Filed: April 11, 2013
    Date of Patent: March 8, 2016
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Marcia MacDonald, Mark Samuels, Robin Sherrington, Yigal Paul Goldberg
  • Synthetic methods for spiro-oxindole compounds
    Patent number: 9260446
    Abstract: This invention is directed to methods of preparing certain spiro-oxindole derivatives, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: February 16, 2016
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Jean-Jacques Alexandre Cadieux, Mikhail Chafeev, Sultan Chowdhury, Jianmin Fu, Qi Ji, Stefanie Abel, Emad El-Sayed, Elke Huthmann, Thomas Isarno
  • SUBSTITUTED BENZOXAZOLES AND METHODS OF USE THEREOF
    Publication number: 20160009667
    Abstract: The invention provides compounds having the general formula (I): and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 14, 2016
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Chien-An CHEN, Sultan CHOWDHURY, Christoph Martin DEHNHARDT, Shaoyi SUN
  • Organic compounds
    Patent number: 9187426
    Abstract: The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Grant
    Filed: June 25, 2009
    Date of Patent: November 17, 2015
    Assignees: Novartis AG, Xenon Pharmaceuticals
    Inventors: Natalie Dales, Zaihui Zhang, Jianmin Fu, Duanjie Hou, Shaoyi Sun, Vishnumurthy Kodumuru, Natalia Pokrovskaia
  • N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF
    Publication number: 20150322002
    Abstract: The invention provides novel compounds having the general formula (I) and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, ring D, R1, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: July 5, 2013
    Publication date: November 12, 2015
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Christoph Martin DEHNHARDT, Sultan CHOWDHURY, Thilo FOCKEN, Michael Edward GRIMWOOD, Ivan William HEMEON, Brian SAFINA, Daniel P. SUTHERLIN
  • N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF
    Publication number: 20150224071
    Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: December 2, 2014
    Publication date: August 13, 2015
    Applicants: XENON PHARMACEUTICALS INC., GENENTECH, INC.
    Inventors: Sultan Chowdhury, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Daniel Ortwine, Brian Safina, Shaoyi Sun, Daniel P. Sutherlin, Alla Yurevna Zenova
  • N-substituted benzamides and methods of use thereof
    Patent number: 8952169
    Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: February 10, 2015
    Assignees: Xenon Pharmaceuticals Inc., Genentech, Inc.
    Inventors: Jean-Christophe Andrez, Sultan Chowdhury, Shannon Marie Decker, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Jun Li, Daniel F. Ortwine, Brian Safina, Tao Sheng, Shaoyi Sun, Daniel P. Sutherlin, Michael Scott Wilson, Alla Yurevna Zenova
  • N-substituted benzamides and methods of use thereof
    Patent number: 8933236
    Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: January 13, 2015
    Assignees: Xenon Pharmaceuticals Inc., Genentech, Inc.
    Inventors: Sultan Chowdhury, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Daniel Ortwine, Brian Safina, Shaoyi Sun, Daniel P. Sutherlin, Alla Yurevna Zenova
  • Spiro-oxindole compounds and their use as therapeutic agents
    Patent number: 8916580
    Abstract: This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: December 23, 2014
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Mikhail Chafeev, Sultan Chowdhury, Lauren Fraser, Jianmin Fu, Jonathan Langille, Shifeng Liu, Jianyu Sun, Shaoyi Sun, Serguei Sviridov, Mark Wood, Alla Yurevna Zenova, Qi Jia, Jean-Jacques Alexandre Cadieux, Simon J. Gauthier, Amy Frances Douglas, Tom Hsieh, Nagasree Chakka, Zoran Cikojevic
  • SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS
    Publication number: 20140336390
    Abstract: This invention is directed to methods of preparing certain spiro-oxindole derivatives, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
    Type: Application
    Filed: May 7, 2014
    Publication date: November 13, 2014
    Applicant: Xenon Pharmaceuticals Inc.
    Inventors: Jean-Jacques Alexandre Cadieux, Mikhail Chafeev, Sultan Chowdhury, Jianmin Fu, Qi Ji, Stefanie Abel, Emad El-Sayed, Elke Huthmann, Thomas Isarno
  • Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
    Patent number: 8883840
    Abstract: This invention is directed to the (S)-enantiomer of the compound of formula (I): or a pharmaceutically acceptable solvate or prodrug thereof. This (S)-enantiomer is useful for the treatment of diseases or conditions, such as pain, which are ameliorated or alleviated by the modulation of voltage-gated sodium channels.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: November 11, 2014
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Mikhail Chafeev, Jianmin Fu, Jean-Jacques Cadieux